Search
for
Sort by
Research 601–630 of 1000+
- Alcohol and Prostate Cancer: Time to Draw Conclusions
- Serum Zinc Levels in Women with Polycystic Ovarian Syndrome are Lower as Compared to Those without Polycystic Ovarian Syndrome: A Cohort Study
- Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells
- CD99 Is Strongly Expressed in Basal Cells of the Normal Adult Epidermis and Some Subpopulations of Appendages: Comparison with Developing Fetal Skin
- Genome-wide p63-Target Gene Analyses Reveal TAp63/NRF2-Dependent Oxidative Stress Responses
- Pancreatogenic type 3C diabetes
- Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation
- A novel 22-bp InDel within <i>FGF7</i> gene is significantly associated with growth traits in goat
- Sox13 is a novel early marker for hair follicle development
- Heterogeneity in the genetic alterations and in the clinical presentation of acrodermatitis enteropathic: Case report and review of the literature
- The exaptation of endocrine pharmacology
- The role of <i>Atg5</i> gene in tumorigenesis under autophagy deficiency conditions
- Nano-pulse stimulation™ therapy (NPS™) is superior to cryoablation in clearing murine melanoma tumors
- Special collection on inward rectifying K<sup>+</sup> channels
- Zinc deficiency is associated with gynecologic cancer recurrence
- Systemic Circulating Leptin – Aiding New Dimension of Immune-Related Skin Carcinogenesis and Lipid Metabolism
- Hair cortisol in polycystic ovary syndrome
- New Perspectives on Nutraceutical Insulin Sensitizing Agents in the Treatment of Psoriasis and Other Dermatological Diseases
- Zinc‐Coordinated Trienzyme Nanogel Cascade Therapy for Accelerated Post‐Pancreatectomy Cutaneous Wound Healing
- Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome K<sub>ATP</sub>Channel Mutations in Intact Cells
- ODAC Chairs Reveal Challenges, High Drama in a Decade of Service
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- XIAP Stabilizes DDRGK1 to Promote ER‐Phagy and Protects Against Noise‐Induced Hearing Loss
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Morphometric prediction of mesenchymal stromal cell-like immunosuppressive capacity of human hair follicle dermal sheath cup cells: an implication for regenerative medicine in hair loss diseases
- Overcoming Curcumin's Limitations: Synthetic Derivatives in Diabetes and Cancer Management
- GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
- New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals
- The TRPM5 Antagonist Triphenylphosphine Oxide Increases Sebaceous Lipogenesis and Modulates Immune Phenotype of Human Sebocytes in a TRPM5‐Independent Manner